Strain D7 of Saccharomyces cerevisiae was used to measure the induction by bleomycin (BLM) of mitotic recombination at the trp5 locus and point mutations at ilv1 in the presence and absence of acridine compounds. BLM is a potent mutagen and recombinagen in the D7 assay. The acridines vary, some being mutagenic or recombinagenic and others not. Combined treatments were used to distinguish whether a genetically inactive acridine has no effect on the genetic activity of BLM or modulates its action. When an acridine is itself genetically active, combined treatments were used to determine whether its effects are additive with those of BLM or whether there is interaction between the two compounds. Acridine compounds that share the ability to intercalate between the base pairs of DNA but differ in their mutagenic specificity owing to the presence of different substituent groups were analysed. Clear potentiation and synergistic interactions were detected in combined treatments with BLM and aminoacridines, nitroacridines or an acridine mustard. Potentiation and synergy were also observed in sequential exposures in which the yeast were grown in the presence of acridine compounds and then treated with BLM in the absence of free acridine. The results are consistent with an increase in BLM susceptibility conferred by acridine intercalation. It is likely that the intercalating agents increase the access of BLM to the minor groove of DNA, where it abstracts a hydrogen from the 4# position of deoxyribose, creating a free radical that is processed into strand breaks.
Introduction
This study evaluates effects of acridine compounds on the genotoxicity of bleomycin (BLM) in Saccharomyces cerevisiae strain D7, a diploid strain constructed by F.K. Zimmermann for the efficient detection of mitotic recombination and point mutations (1, 2) . Recombinagenic effects were measured by a positive selection for gene conversion at the trp5 locus, and mutagenic activity was measured by quantifying reversion of the ilv1-92 allele (3, 4) . The assay for gene conversion in D7 and the related strain D4 is based on the trp5-12 and trp5-27 alleles (2, 5) . These well-characterized strains have been used to evaluate .200 chemicals for recombinagenic activity. Besides the end points studied here, D7 permits the detection of reciprocal mitotic recombination as sectored red and pink twin-spot colonies that arise by crossing over between the centromere and the ade2 locus (3, 4) .
The cancer chemotherapy drug BLM is a mixture of glycopeptide antibiotics isolated from Streptomyces verticillus. The clinically used form of the drug, called Blenoxane, contains 60% BLM A 2 , 30% BLM B 2 and other minor components (6, 7) . BLM induces DNA damage by an indirect genetic mechanism whose steps have been largely elucidated (7, 8) . BLM associates with DNA non-covalently by intercalation or interaction with the minor groove (7) . A chelated metal atom, usually iron, in the BLM molecule serves as a centre for the activation of BLM (9) . Molecular oxygen and an electron source are needed for the activation of Fe(II)-BLM to a form that abstracts a hydrogen from the 4# position of deoxyribose in the minor groove of DNA (8) (9) (10) . Processing of the free radical at 4# leads to single-and double-strand breaks in DNA (7, 8) with specificity for 5#-guanine-pyrimidine-3# sites (7) . Reactivation of the same BLM molecule in situ apparently explains the high frequency at which BLM-induced single-strand breaks are converted into double-strand breaks (10, 11) . Double-strand breaks are responsible for cytotoxic (9, 10, 12) and clastogenic effects of BLM, including chromosome aberrations and micronuclei (8, 13, 14) , and they are initiating lesions in the induction of mitotic recombination (4, 15) . BLM also induces point mutations, perhaps through imperfect repair of breaks (7) . The mutations include base pair substitutions, À1 frameshifts and small deletions (7, 8) .
Acridines are of interest as model compounds for genetic and structural studies and for their many uses, notably including dyes and drugs (16) . They are planar heterocyclic molecules with three fused rings whose dimensions resemble a DNA base pair and favour intercalation between the base pairs, lying parallel to the bases and perpendicular to the axis of the double helix (17, 18) . The structures of the acridine compounds used in this study are shown in Figure 1 . The association between acridine compounds and DNA is favoured by a positive charge on the ring system or on substituent groups, making many aminoacridine derivatives effective intercalators. However, the intercalation geometry of different chemicals can vary owing to substituent groups. For example, acridine orange (Figure 1 ), which has methyl groups replacing the hydrogens on the amino groups of proflavine, cannot form hydrogen bonds as proflavine does, and this makes its intercalation geometry asymmetric (18) .
The frameshift mutagenicity of proflavine and acridine yellow was used in the rationale of classic studies that demonstrated the triplet nature of the genetic code (19) , and acridines have been widely known ever since as frameshift mutagens (16, 20, 21) . Aminoacridine derivatives that do not react with DNA covalently, such as 9-aminoacridine (9AA), can be thought of as simple intercalators, and they tend to induce þ1 and À1 frameshift mutations in bacteria by a slipped mispairing *To whom correspondence should be addressed. Tel: þ1 508 793 3416; Fax: þ1 508 793 2696; Email: ghoffmann@holycross.edu mechanism at monotonous runs of a single base (22) (23) (24) . Acridines with reactive substituent groups, such as nitroacridines and acridine mustards, can form covalent adducts in DNA as well as intercalating, and they often induce a broader array of genetic alterations than do the simple intercalators (16, 23, 24) .
In contrast to their effects in bacteria, where they are potent inducers of frameshift mutations that arise by slipped mispairing in repetitive sequences (23, 24) , simple intercalators such as 9AA have less potent genotoxic effects in eukaryotes (16, 21) . Those intercalators that are genetically active commonly act as topoisomerase-II poisons that stabilize the enzyme-DNA cleavable complexes leading to breaks in DNA (21, 25) . The increase in double-strand breaks can explain the induction of chromosomal damage and mitotic recombination by acridines in eukaryotes (16, 21, 25) . In contrast, catalytic inhibitors of topoisomerase-II, including some acridines, block the activity of topoisomerase-II before it produces double-strand breaks, and they can thereby reduce the activity of clastogens that act as topoisomerase-II poisons (25) . The mechanisms of genotoxicity of acridines, which depend on repetitive sequences (16, 20, 21, 23, 24) or topoisomerase interactions (21, 25) , differ sharply from that of BLM, which depends on neither (7) (8) (9) 26) .
Interactions of BLM with other agents are of interest on several grounds. Measurement of the potentiation of BLM genotoxicity has been proposed as an assay to identify and explore the effects of intercalating agents (27) (28) (29) (30) . Understanding BLM interactions also has implications for BLM therapy, as modulators that increase the potency of BLM may be exploitable if the effects can be targeted to tumour cells but may pose a hazard if the enhanced toxicity occurs in non-tumour cells; the reverse would be true of modulators that decrease the activity of BLM (31) (32) (33) . At a more basic level, effects of other chemicals on BLM activity can provide insight into the modulation of mutagenic activity more generally, including antimutagenic effects, potentiation of genotoxicity and synergistic and antagonistic interactions among mutagens (33) (34) (35) . There is not only interest in potential benefits to be derived from antimutagenicity (36) (37) (38) but also concerns about unforeseen hazards of potentiation (32, 33, 39) .
In a previous paper, we reported several mechanisms by which amines reduce or enhance the induction of gene conversion by BLM in yeast strain D7 (33) . Among the interactions was enhancement of the recombinagenicity of BLM by the acridine compounds 9AA and Entozon. The present studies extend these findings to other acridine compounds, measuring both mitotic recombination and point mutations and exploring the effects of separate intercalation and BLM treatment. The acridine compounds include simple intercalators and derivatives that form adducts in DNA through reactive substituent groups.
Materials and methods
Chemicals BLM [bleomycin sulphate; Chemical Abstracts Service Registry Number (CAS) 9041-93-4] was purchased from Sigma-Aldrich Chemical Company, St Louis, MO. Frozen BLM solutions in distilled water were stored at À20°C in 0.25 ml aliquots at 4 mg/ml with no change in genetic activity in repeated experiments. Quinacrine (quinacrine dihydrochloride; CAS 69-05-6), quinacrine mustard (quinacrine mustard dihydrochloride; CAS 4213-45-0), 9AA (9-aminoacridine hydrochloride; CAS 134-50-9), proflavine (proflavine hydrochloride; CAS 952-23-8) and acridine orange [3,6-bis-(dimethylamino)acridine hydrochloride zinc chloride double salt; CAS 10127-02-3] were also from Sigma-Aldrich. 9-(3#-Dimethylaminopropylamino)-acridine diHCl (DAPA), nitracrine dihydrochloride (ledakrin; 1-nitro-DAPA diHCl; CAS 6514-85-8), and the 2-, 3-, and 4-nitro isomers (2-, 3-, and 4-nitro-DAPA) were provided by W.A. Denny. They were synthesized in the Auckland Cancer Society Research Centre, University of Auckland, New Zealand, using published methods (40) (41) (42) . The biological activity of the acridine compounds, stored as frozen stock solutions at 2048 lM, remains constant for several months or longer.
Media
Yeast Extract Peptone Glucose Medium (YEPD) contained 1% Difco yeast extract, 2% Difco peptone and 2% D-glucose (1) . Minimal medium for measuring cell densities and toxicity (YMAIT) contained 2% glucose, 0.67% Difco Yeast Nitrogen Base without amino acids, adenine sulphate (5 mg/l), isoleucine (60 mg/l), tryptophan (10 mg/l) and 2% Difco Bacto-agar (1). Tryptophan was omitted from the medium (YMAI) to select Trp þ convertants, and isoleucine was omitted (YMAT) to detect Ilv þ revertants.
Microbiological methods
Saccharomyces cerevisiae strain D7 (a ade2-40 trp5-12 ilv1-92/a ade2-119 trp5-27 ilv1-92) was from F.K. Zimmermann (Technische Hochschule, Darmstadt, Germany). Procedures for handling strain D7 were based on previously reported methods (1) (2) (3) (4) (5) 43) . Single colonies were isolated from YEPD or YMAIT plates and grown to stationary phase in YEPD. Cell densities were determined by plating on YMAIT, and spontaneous frequencies of trp5 convertants and ilv1 revertants were determined by plating on YMAI and YMAT, respectively. Total colonies and Trp þ convertants were counted after 3 days incubation at 28°C and Ilv þ revertants after 4 days. Cultures with known spontaneous convertant and revertant frequencies were stored at 4°C and used for experiments over a period of 4-6 weeks. Thus, the spontaneous frequencies were less affected by random events occurring early in the history of a culture than would be the case if uncharacterized cultures from isolated colonies were used. Spontaneous convertant and revertant frequencies in all experiments were consistent with our historical controls and values in published literature.
Mutagenic treatment
Cotreatments with acridine compounds and BLM used dividing cells of strain D7 in YEPD. Treatments were initiated by inoculating 20 ll of a yeast culture whose spontaneous convertant and revertant frequencies had been 
G. R. Hoffmann et al.
characterized into 1 ml YEPD with or without BLM and acridines. The tubes were incubated in a shaker for 16-18 h at 28°C. Although imprecise, we estimate that the yeast underwent five to seven cell divisions in the treatment period. Treatments were terminated by diluting 1:10 in cold saline (0.9% NaCl), centrifuging 15 min at 2000 r.p.m. in a Beckman TJ-6 centrifuge and re-suspending in fresh saline for dilution and plating.
Sequential treatments entailed growth in YEPD containing an acridine compound for 18 h, dilution (1:10) in cold saline, centrifugation, re-suspension in 50 mM phosphate buffer (pH 7) containing BLM without acridines and incubation in a shaker bath at 28°C for 2 h. The BLM treatment was terminated by dilution in cold saline, centrifugation and re-suspension in saline.
Quantification of toxicity, convertants and revertants Chemically treated yeast were diluted in saline and surface plated on YMAIT, YMAI and YMAT to quantify cell numbers, convertants and revertants, respectively. Unless otherwise noted, the cell densities for plating were $2 Â 10 7 cells per revertant selection plate, 2 Â 10 6 per convertant selection plate and 150 on supplemented medium to measure cell density (i.e. numbers of colony-forming units). Toxicity was expressed as a relative cell density (RCD), which is the number of colony-forming cells per millilitre relative to that of the untreated control. These procedures measure convertant and revertant frequencies, not rates of mitotic recombination or mutation per cell generation. Frequencies of genetic alterations were expressed as convertants per 10 5 viable cells AE SEM and revertants per 10 6 viable cells AE SEM. The data in the tables represent means and standard errors from three replicate plates. All conclusions from these tables were confirmed in independent experiments that supported the same interpretations. In measuring interactions, we distinguished between potentiation and synergy. Potentiation refers to the enhancement of BLM activity by an acridine that is not itself active in the assay; synergy refers to an interaction in which both BLM and the acridine are active, and the effect of the combined treatment is greater than the sum of the separate treatments.
Results
Because of the need for acridines to intercalate into DNA to have their effects, we conducted our cotreatments with BLM and acridines in rich growth medium (YEPD). To ensure that the conditions were suitable for treating actively growing cells, we initially monitored growth of D7 at various times by optical density readings, proportions of cells with and without buds, and cell densities determined by haemocytometer counts and by plating; we found a 16-to 18-h incubation optimal for treating throughout the period of exponential growth and terminating treatments when cultures were still vigorous but in the transition to stationary phase. BLM is a potent recombinagen and mutagen in the D7 assay under these conditions.
The induction of trp5 gene conversion and reversion of the ilv1-92 allele by BLM in a 16-h treatment of exponentially growing cells in rich medium (YEPD) is shown in Figure 2 . The dose dependence of the induction is reflected in the strongly positive slopes of the responses for both convertants (P , 0.0001; r 2 5 0.94) and revertants (P , 0.0001; r 2 5 0.95). We chose the BLM doses of 0.2 and 0.4 lg/ml for studies of compounds that may enhance BLM genotoxicity, as these doses induce highly significant increases in Trp þ convertants and Ilv þ revertants (P , 0.001; Bonferroni multiple comparisons test), yet they are only modestly toxic using the criterion of a reduction in the cell density of the culture.
The effect of the intercalating agent DAPA on the genetic activity of BLM in D7 is shown in Table I . The treatments with BLM alone confirm earlier studies in showing that low concentrations of BLM induce gene conversion and mutations in growing cells (4; Figure 2 ). The decline in cell density reflects dose-dependent toxicity. Given that the treatments were in growth medium, this decline is not equivalent to survival measured for treatments of non-growing cells in buffer. Instead, it is a complex measure of toxicity that can include cell killing, slowing of growth and a lower cell density of the plateau as cultures approach stationary phase. DAPA is neither recombinagenic nor mutagenic in the D7 assay under the same conditions where BLM induces gene conversion at the trp5 locus and reversion of ilv1-92. In combined treatments, however, DAPA potentiates both the recombinagenic and mutagenic effects of BLM. The potentiation is dose dependent, leading to convertant and revertant frequencies several fold higher than those caused by BLM alone. There is a highly significant enhancement of BLM activity by DAPA.
Four isomeric nitro derivatives of DAPA were studied to determine whether they potentiate BLM in D7 similarly to the parent compound. Nitracrine, the 1-nitro isomer, induces gene conversion at the trp5 locus and reversion of the ilv1-92 allele. Table II , part A, shows the dose dependence of the genotoxic responses to nitracrine in the absence of BLM and of BLM in the absence of nitracrine. The convertant and revertant frequencies detected in combined treatments with BLM and nitracrine reflect strong recombinagenic and mutagenic effects. An analysis of whether the effects of BLM and nitracrine are additive was performed by comparing the sum of the treatments for each chemical alone with the combined treatment. Means and standard errors were generated by a bootstrap method using the program Resampling Stats 4.1; data were resampled 15 000 times using per-plate convertant and revertant frequencies and scaling the SEM values to three replicate plates. A two-tailed t-test was used to compare the mean and standard error for the sum of treatments with the corresponding combined treatment. The data in part B of Table II indicate that there is a synergistic interaction between BLM and nitracrine in inducing gene conversion and point mutations, in that the combined effects are significantly greater than additive. Table III shows that 2-nitro-DAPA is essentially inactive in D7, showing only a small increase in convertant frequency at the highest dose. However, in combination with BLM, it caused highly significant increases in convertant and revertant frequencies above those induced by BLM alone. A test for interactions (Table III , part B) confirms this interpretation. The 3-nitro analogue of DAPA was inactive alone but it, too, strongly potentiated the mutagenic and recombinagenic effect of BLM (Table IV) . Growing cells were treated with BLM and/or NC in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.42 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with NC and the untreated control and between the combined BLM-NC treatments and the same BLM treatment in the absence of NC was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P , 0.01; ***P , 0.001). The test for interaction was a two-tailed t-test comparing frequencies of induced convertants and revertants (spontaneous subtracted) in the combined treatment with those in the sum of the separate treatments, using means and error terms generated by resampling statistics (*P , 0.05; **P , 0.01; ***P , 0.001). Growing cells were treated with BLM and/or DAPA in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.47 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with DAPA and the untreated control and between the combined BLM-DAPA treatments and the same BLM treatment in the absence of DAPA was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P , 0.01; ***P , 0.001).
4-nitro-DAPA in the induction of gene conversion at the trp5 locus, in that the effects of the combined treatments are significantly greater than the sums of separate treatments. Although its activity in the reversion assay was negligible, 4-nitro-DAPA potentiates the induction of reversion by BLM.
The non-reactive intercalating agent quinacrine and its reactive counterpart quinacrine mustard were tested concurrently. Data are presented in Tables VI and VII. Quinacrine was neither recombinagenic nor mutagenic in D7 (Table VI) , whereas quinacrine mustard was weakly genotoxic in both the mutagenicity and recombinagenicity assays (Table VII, part A). Both compounds enhanced the induction by BLM of gene conversion at the trp5 locus and reversion of the ilv1-92 allele. The potentiation of BLM by quinacrine is indicated by Growing cells were treated with BLM and/or 2ND in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.89 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with 2ND and the untreated control and between the combined BLM-2ND treatments and the same BLM treatment in the absence of 2ND was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P , 0.01; ***P , 0.001). The test for interaction was a two-tailed t-test comparing frequencies of induced convertants and revertants (spontaneous subtracted) in the combined treatment with those in the sum of the separate treatments, using means and error terms generated by resampling statistics (*P , 0.05; **P , 0.01; ***P , 0.001). Growing cells were treated with BLM and/or 3ND in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.83 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with 3ND and the untreated control and between the combined BLM-3ND treatments and the same BLM treatment in the absence of 3ND was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P , 0.01; ***P , 0.001).
dose-dependent increases in convertant and revertant frequencies in combined treatments, while quinacrine alone showed no significant differences from the untreated control. In the case of quinacrine mustard, an interaction test was used to determine whether the mutagenic effects of the compound were additive or synergistic with those of BLM (Table VII , part B) . The results show a highly significant synergistic interaction between BLM and quinacrine mustard.
The well-known intercalating agent proflavine was recombinagenic but not mutagenic in the D7 assay (Table VIII, part A). In combined treatments, it potentiated the mutagenic effect of BLM and acted synergistically with BLM in the induction of Growing cells were treated with BLM and/or 4ND in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.80 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with 4ND and the untreated control and between the combined BLM-4ND treatments and the same BLM treatment in the absence of 4ND was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P , 0.01; ***P , 0.001). The test for interaction was a two-tailed t-test comparing frequencies of induced convertants and revertants (spontaneous subtracted) in the combined treatment with those in the sum of the separate treatments, using means and error terms generated by resampling statistics (*P , 0.05; **P , 0.01; ***P , 0.001). Growing cells were treated with BLM and/or quinacrine in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.60 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with quinacrine and the untreated control and between the combined BLMquinacrine treatments and the same BLM treatment in the absence of quinacrine was determined by analysis of variance with Bonferroni multiple comparison tests (NS, non-significant; *P , 0.05; **P , 0.01; ***P , 0.001).
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gene conversion (Table VIII , part B). The related compound acridine orange induced neither genetic effect in D7 (Table IX) . However, dose-dependent increases in convertant and revertant frequencies in combined treatments with BLM indicate that acridine orange potentiates BLM. Table X shows results for the induction of gene conversion and point mutations by the treatment of growing cells with 9AA and seven derivatives of 9AA using a procedure that separates acridine intercalation from BLM treatment. The yeast were grown in the presence of acridines, harvested by centrifugation and washed in buffer prior to BLM treatment in buffer. The recombinagenic (part A) and mutagenic effects (part B) were greater for the sequential acridine-BLM treatments than for the sum of the individual treatments. Thus, potentiation or synergy occurs, even though the BLM treatment occurred in the absence of free acridine.
Discussion
When testing cells in growth medium for genotoxicity using selective media, one must be attentive to the possibility of selection for existing convertants or revertants, which could resemble the induction of new convertants or revertants. Nevertheless, treatment in growth medium is common in yeast assays. In an international collaborative programme on assays, most laboratories reported treating growing yeast for 16-24 h in complete medium (44) , and Zimmermann and Scheel (43) reported that a 15-to 17-h treatment in YEPD or synthetic growth medium (45) is effective for strain D7. The assay for mitotic recombination and reversion in strain D7 is a wellvalidated method for which the concern about selection artefacts has been discussed by Zimmermann et al. (5) in a critical evaluation of yeast assays organized by the US Environmental Protection Agency. They recommended that cultures be monitored for normal spontaneous frequencies of convertants and revertants; treatments use actively growing cells; and incubation should only slightly exceed the time required to reach stationary phase, thus avoiding extended incubations that can be problematic with respect to selection favouring prototrophs, especially when synthetic minimal medium is used rather than a rich medium such as YEPD (5) . Our experiments conform to these protocol recommendations.
In addition to using validated methods, we ruled out the possibility of selection by measuring the spontaneous frequency of Trp þ convertants and Ilv þ revertants after incubation in YEPD for various times. The convertant and revertant frequencies were stable and consistent with historical controls when yeast were plated after 6, 9, 12, 15 and 24 h. Although we would not recommend longer growth periods, we tested them to determine whether frequencies of prototrophs increased. An increase in apparent convertant frequency occurred reproducibly in a 96-h incubation; there was no increase in convertant or revertant frequencies after 48-or 72-h incubation in YEPD. With respect to BLM treatments, we would note that dose-dependent increases in convertant and revertant frequencies occur not only in growth medium but also in treatments of non-growing cells in buffer, where an absolute increase in numbers of convertants and revertants can be ascribed only to induction (33,46, Table X ).
There are diverse mechanisms by which compounds can modulate the genotoxic activity of BLM. These include changing Growing cells were treated with BLM and/or QM in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.60 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with QM and the untreated control and between the combined BLM-QM treatments and the same BLM treatment in the absence of QM was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P ,0.01; ***P , 0.001). The test for interaction was a two-tailed t-test comparing frequencies of induced convertants and revertants (spontaneous subtracted) in the combined treatment with those in the sum of the separate treatments, using means and error terms generated by resampling statistics (*P , 0.05; **P , 0.01; ***P , 0.001).
BLM's access to DNA through intercalation or other noncovalent DNA interactions, modification of oxygen tensions, altering BLM uptake by cells, increasing or decreasing levels of BLM hydrolase, changing cellular redox potential or modifying cellular repair capacity (25, 33) . Among these, intercalation is a prevalent mechanism shared by many compounds (25) , of which acridines are classical intercalators (16) (17) (18) 20, 21) .
Previous studies using the assay for gene conversion at the trp5 locus in strain D7 have shown that amines modulate the genetic activity of BLM in yeast by at least four mechanisms (33) . These interactions include antigenotoxic, potentiating and synergistic effects. Unbranched aliphatic amines, such as spermidine and spermine, protect against the effects of BLM. The antigenotoxic effect is stronger for more strongly cationic amines, and this result is consistent with an electrostatic association of the amines with DNA hindering the access of BLM to DNA (33) . In contrast, other amines show complex patterns depending on physiological conditions. The aminothiol cysteamine inhibits the genotoxicity of BLM under hypoxic conditions but increases it under euoxic conditions, whereas pargyline potentiates the genotoxicity of BLM under hypoxic conditions but not under euoxic conditions (33) . The protective effects of aminothiols apparently result from their ability to bind to DNA and deplete oxygen needed for BLM activity, whereas their potentiating influence stems from their ability to serve as electron donors for the activation of BLM (33, 46) . In the case of pargyline, preferential activity under hypoxic conditions probably relates to inhibition of monoamine and polyamine oxidase, preventing the depletion of oxygen needed for BLM activation (33) . Another interaction observed in yeast was the enhancement of BLM's induction of mitotic recombination by the acridine compounds 9AA and Entozon, which intercalate into DNA (33) .
All 10 acridine compounds included in this study enhance the recombinagenic and mutagenic effects of BLM in yeast strain D7 (Tables I-X) . Besides evaluating interactions with BLM, our results indicate genetic activity of some of the acridines in the absence of BLM. These results are largely consistent with published literature for those acridines that have been tested previously for recombinagenic activity, and they extend the literature in instances where there have not been previous tests. BLM alone is a potent recombinagen in the D7 assay (33, 46) and effectively reverts ilv1-92 in this strain (Tables I-X) .
Studies comparing different strains and loci have shown that the ilv1-92 allele is especially responsive to the mutagenicity of BLM (47) . This result is compatible with the known mutation spectrum of BLM, in that ilv1-92 responds well to inducers of base pair substitutions (3) . BLM preferentially induces DNA damage on pyrimidine residues that are 3# to guanine (7, 48, 49) . Its mutation spectrum in phage k includes a majority Growing cells were treated with BLM and/or PF in YEPD for 16 h at 28°C in a shaker. The cell density of the untreated control culture was 1.26 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with PF and the untreated control and between the combined BLM-PF treatments and the same BLM treatment in the absence of PF was determined by analysis of variance with Bonferroni multiple comparison tests (NS, non-significant; *P , 0.05; **P , 0.01; ***P , 0.001). The test for interaction was a two-tailed t-test comparing frequencies of induced convertants and revertants (spontaneous subtracted) in the combined treatment with those in the sum of the separate treatments, using means and error terms generated by resampling statistics (*P , 0.05; **P , 0.01; ***P , 0.001).
of transitions and transversions at G-T or G-C dinucleotides, but there are also mutations originating at A:T base pairs and À1 frameshifts (48) . The spectrum of BLM-induced mutations at the aprt locus in CHO cells included a majority of À1 frameshift mutations, which may arise by inaccurate repair of double-strand breaks at BLM's 5#-G-C-3# and 5#-G-T-3# cleavage sites, and a minority of base pair substitutions both at A:T and G:C base pairs (50) . Although ilv1-92 has not been characterized at the sequence level, genetic evidence indicates that it is suppressible, and it appears to be a missense allele (51) . In haploid strains, ilv1-92 reverts by true back mutations and by suppressor mutations, making it responsive to agents that act through various mechanisms (3, (51) (52) (53) . One might expect the spectrum of detected mutations to be more restricted in diploids like D7 because recessive suppressors would not be detected (5) . However, the fact that revertant frequencies induced by mechanistically different mutagens are only slightly lower in diploid strains than in haploid strains is consistent with diverse events being detected (51) . We suspect that BLMinduced revertants in D7 principally reflect base pair substitution mutagenesis, but they may include some frameshifts. Among the acridines, only nitracrine and quinacrine mustard unequivocally induced reversion of ilv1-92 (Tables II, VII and X) .
A comprehensive literature survey by Zimmermann et al. (5) on genotoxicity in yeast reported that 9AA (called 5-aminoacridine using different numbering) induces forward mutations but had not been tested for recombinagenic activity. Recent literature searches suggest that that has not changed. We found 9AA to be a modest inducer of gene conversion (33; Table X), a result that was reproducible in five independent experiments. Yet the induction of gene conversion was not detected for the related simple intercalators DAPA (Table I) and quinacrine (Table VI) . We observed a recombinagenic effect of proflavine (Table VIII) , as had been reported earlier (5, 54, 55) , but not of the related compound acridine orange (Table IX) . Acridine orange has been reported elsewhere to be recombinagenic in yeast (5, (54) (55) (56) (57) , albeit under different conditions, but its potency tends to be modest compared to other recombinagens (56, 57) , and several yeast tests for mitotic crossing over have yielded negative results (56,57). Taken as a whole, the results are consistent with acridine orange being weakly recombinagenic.
We found quinacrine mustard (Table VII) but not quinacrine (Table VI) to induce gene conversion. We are not aware of previous assays of these compounds in yeast. The genetic toxicology of quinacrine has generated renewed interest because of the controversial recent use of this former antimalarial drug for non-surgical sterilization in women (58) (59) (60) . Quinacrine is a frameshift mutagen in bacteria (16, 23, 61) , and it has been reported to induce gene mutations (61) , chromosome aberrations (61) and sister chromatid exchange (16) in cultured mammalian cells, but results in a mouse bone marrow micronucleus assay were negative (61) . Although active in various genotoxicity assays (16, 23, 61) , it did not induce gene conversion in D7 in four experiments. Yet, its potentiation of BLM (Table VI) is consistent with its activity as an intercalating agent.
DAPA and its nitro derivatives, including the cancer chemotherapy drug nitracrine, have been evaluated for activity in several genetic toxicology assays. The Ames assay (62) and the lacZ reversion assay in Escherichia coli (24) were consistent in showing DAPA to be a potent bacterial mutagen, inducing AE1 frameshift mutations in runs of G:C base pairs. Its nitro derivatives, especially nitracrine and 3-nitro-DAPA, induce a more diverse array of frameshifts, including À2 frameshifts. The difference in the spectrum of mutations can be ascribed to DAPA acting exclusively as an intercalating agent, whereas the 1-, 3-and 4-nitroacridines can undergo nitroreduction, giving rise to reactive derivatives that form covalent adducts in DNA (16, 24) . Among the nitro-DAPA isomers, 2-nitro-DAPA most closely resembles DAPA in mutagenicity (24) , which is consistent with its being least susceptible to nitroreduction (16) .
In our study, nitracrine was clearly mutagenic and recombinagenic in yeast (Table II) , while 4-nitro-DAPA was recombinagenic but not mutagenic or very weakly so (Table V) . DAPA and its 3-nitro derivative were inactive for both genetic end points (Tables I and IV) ; 2-nitro-DAPA was also negative for mutations but equivocal for mitotic recombination (Table III) . Our results for nitracrine and 4-nitro-DAPA Growing cells were treated with BLM and/or AO in YEPD for 18 h at 28°C in a shaker. The cell density of the untreated control culture was 1.60 Â 10 8 cells/ml. b Frequencies are means AE SEMs. The significance of differences between treatments with AO and the untreated control and between the combined BLM-AO treatments and the same BLM treatment in the absence of AO was determined by analysis of variance with Bonferroni multiple comparison tests (NS, nonsignificant; *P , 0.05; **P , 0.01; ***P , 0.001).
confirm the findings of Ferguson and Turner (63) that these compounds are effective recombinagens in yeast strains D5 and D7. They reported the recombinagenicity of the compounds in the order nitracrine . 4-nitro .. 3-nitro ! 2-nitro % DAPA, with DAPA being essentially inactive. Our results are also consistent with Ferguson and Turner (63) in finding the toxicity of nitracrine, as indicated by RCD, to be much greater than that of DAPA or any of the other nitro-DAPA isomers.
Independently of whether they were themselves active in the D7 assay, all the acridines potentiated the induction of trp5 gene conversion and reversion of ilv1-92 by BLM in growing cells (Tables I-IX) . Potentiation was also seen when intercalation was separated from BLM treatment by growing the yeast in the presence of acridines, centrifugation and washing away the free acridine before treating non-growing cells for 2 h with BLM in buffer (Table X) . In essentially all cases, the effects of the sequential treatments were greater than the sum of the separate treatments even though the BLM treatment occurred in the absence of free acridine. In some instances (e.g. DAPA, 2-nitro-DAPA and quinacrine in the reversion assay), the difference did not rise to the level of statistical significance under these conditions (0.1 , P , 0.2), but the The significance of the differences of acridine treatments from the untreated control was determined by analysis of variance with a Bonferroni multiple comparison test (NS, non-significant; *P , 0.05; **P , 0.01; ***P , 0.001). All BLM treatments differed significantly from the untreated control. d The test for interaction was a two-tailed t-test comparing the sequential treatment with the sum of measurements from the separate treatments using error terms generated by resampling statistics (*P , 0.05; **P , 0.01; ***P , 0.001).
activity of the acridines in potentiating BLM in these cases is evident in the experiments in growing cells. The difference undoubtedly reflects lesser sensitivity of the method of separate intercalation and short-term BLM treatment in buffer than the extended cotreatment of growing cells. The most likely explanation for the fact that all the acridines exhibit potentiation of BLM or synergy with BLM for both gene conversion and reversion in the D7 assay is that intercalation enhances access of BLM to its target at the 4#-position of deoxyribose in the minor groove of DNA. The first step in BLM activity is its noncovalent binding to DNA, and this binding may be facilitated by the conformational alterations caused by bound acridines.
Snyder and colleagues proposed that potentiation of BLM can serve as an assay for intercalating agents. Their BLM amplification assay measures enhancement of a 3-h treatment with BLM at 5 lg/ml in the Chinese hamster V79 micronucleus assay (25, 27) . The interpretation that BLM amplification can be ascribed to intercalation is supported by a DNA-docking model that uses computer simulation to predict non-covalent DNA interactions of molecules on the basis of their chemical structures (25, (28) (29) (30) . On the basis of this assay, Snyder et al. (28, 30) defined an intercalation potency factor (IPF) as the slope of the plot of fold increase in micronucleus frequency versus micromolarity of modulator Â 100.
We used several measures to quantify the potency of interactions between BLM and intercalating agents in yeast. While the IPF of Snyder et al. (28, 30 ) is a straightforward comparison of relative potencies, its use of an absolute concentration (lM) can make it somewhat assay specific because such factors as permeability may override inherent differences among compounds in intercalation. Moreover, the IPF is more readily applied when the modulator itself is genetically inactive than when it is genotoxic in the absence of BLM. Our study requires differentiation between potentiation of BLM by a modulator that is not itself genotoxic and synergy between BLM and a genotoxic modulator. We therefore explored alternative measures of the potency of the interaction between BLM and modulators that can be applied when both agents are genotoxic. Net change in induced convertant or revertant frequency ascribable to the modulation of BLM was calculated as a frequency induced by a combined treatment, subtracting out spontaneous events and those ascribable to BLM alone or the modulator alone. This measure was too variable to permit useful comparisons among chemicals, especially since it is disproportionately affected by data points at moderate to high toxicity, which represent the least stable part of the dose-response curve.
We prefer to express the potency of interactions as an Index of Interaction (I i ), defined as the ratio of the effect of a combined treatment to that of the sum of separate treatments. The I i is suitable when both agents are active or when only one is active, and it may be calculated for convertant frequencies, mutation frequencies or any other indicator of effect. For convertant frequencies, I i(CF) is calculated as follows: where I i(CF) is the ratio of the induced convertant frequency of the combined treatment to that of the sum of the separate treatments; CF B þ mod is the convertant frequency from the combined treatment with BLM þ modulator; CF 0 is the spontaneous convertant frequency; CF B is the convertant frequency from treatment with BLM alone and CF mod is the convertant frequency from treatment with modulator alone. Values significantly .1 indicate potentiation or synergy, whereas those significantly ,1 indicate protection or antagonism. Slopes of I i values are analogous to Snyder's IPF (28) but they encompass synergy, as well as potentiation. Of the acridines studied, all had I i values significantly .1 and slopes greater than zero, indicating potentiation and synergy, yet only nitracrine differed sharply from the other compounds in slope. The slopes for the other acridines relative to DAPA (1.0) were 0.8 for 9AA, 1.4 for quinacrine, 0.8 for quinacrine mustard, 3.4 for proflavine, 2.7 for acridine orange, 62.1 for nitracrine and 0.4, 1.6 and 0.5 for 2-, 3-and 4-nitro-DAPA, respectively. The high value for nitracrine reflects its activity at very low concentrations. The 4-fold difference in slope between 9AA and proflavine that we observed in yeast is parallel to the IPF values of 11.8 for 9AA and 50 for proflavine reported by Snyder et al. (28) in mammalian cells.
We also considered quantifying the interactions in ways that do not emphasize absolute concentrations. Calculations of convertant and revertant frequencies at the dose required to reduce the RCD by one-third rank nitracrine and DAPA as roughly equal in enhancing BLM activity, suggesting that both potentiate BLM only when they become toxic. The data as a whole suggest that potentiation or synergy is primarily a function of the toxicity of the combined treatment. This interpretation is supported by the observation that the I i for all chemicals reaches a value of 2 only when the RCD ,0.33. It is also supported by the fact that I i values correlate more strongly with toxicity (Spearman correlation coefficients r 5 0.76 for 1 À RCD and either I i(CF) or I i(RF) ) than with dose itself (r 5 0.64 for I i(CF) and 0.63 for I i(RF) ). Thus, the data do not support the interpretation that some acridines potentiate BLM at subtoxic doses whereas others are only effective in the toxic range. Instead, toxicity is closely associated with the potentiating activity of all these compounds, suggesting that the toxicity and the potentiation of BLM are both effects of intercalation.
In conclusion, the simple intercalator DAPA is not genetically active in yeast strain D7, but it enhances the potent mutagenic and recombinagenic effects of BLM. Nitracrine, which is a reactive derivative of DAPA that forms adducts in DNA, is recombinagenic and mutagenic in D7, and it acts synergistically with BLM. Synergistic interactions were distinguished from additive effects by comparing genetic effects of combined treatments with BLM and acridines to the sum of the separate treatments. Ten acridine compounds were evaluated for interactions with BLM, and all enhanced its mutagenic and recombinagenic activity. The data are summarized in Table XI . The potency of the interactions correlated with the toxicity of the combined treatments. The acridines were similar to each other in potency except for nitracrine, which was roughly 50-fold more active. Our findings with acridines and BLM in yeast are consistent with the interpretation of Snyder and colleagues based on micronucleus assays in mammalian cells that potentiation of BLM is characteristic of intercalating agents (27) (28) (29) . Acridine intercalation apparently gives BLM greater access to the minor groove where it abstracts a hydrogen from the 4# position of deoxyribose, generating a free radical that is processed into DNA strand breaks.
Funding
This work was supported by the Simeon J. Fortin Charitable Trust and a Robert J. Stransky Research Fellowship.
